PrintDownload PDFGet Adobe ReaderDownload to WordDownload as HTMLDownload as XMLCitation Manager
Save to Favorites
Guideline Summary
Guideline Title
ACMG practice guideline: lack of evidence for MTHFR polymorphism testing.
Bibliographic Source(s)
Hickey SE, Curry CJ, Toriello HV. ACMG practice guideline: lack of evidence for MTHFR polymorphism testing. Genet Med. 2013 Feb;15(2):153-6. [77 references] PubMed External Web Site Policy
Guideline Status

This is the current release of the guideline.

Scope

Disease/Condition(s)

Thrombophilia

Guideline Category
Assessment of Therapeutic Effectiveness
Counseling
Evaluation
Clinical Specialty
Family Practice
Hematology
Medical Genetics
Obstetrics and Gynecology
Intended Users
Physicians
Guideline Objective(s)

To review the latest evidence on 5,10-methylenetetrahydrofolate reductase (MTHFR) polymorphism testing as part of a routine evaluation for thrombophilia

Target Population

Women of childbearing age and patients at risk for thrombophilia

Interventions and Practices Considered
  1. 5,10-methylenetetrahydrofolate reductase (MTHFR) polymorphism testing (not recommended)
  2. Evaluation of symptoms in patients in whom an MTHFR polymorphism(s) is found
  3. Fasting total plasma homocysteine
  4. Folic acid supplementation
Major Outcomes Considered

Not stated

Methodology

Methods Used to Collect/Select the Evidence
Hand-searches of Published Literature (Primary Sources)
Hand-searches of Published Literature (Secondary Sources)
Searches of Electronic Databases
Description of Methods Used to Collect/Select the Evidence

The guideline authors searched PubMed and the Cochrane Database of Systematic Reviews from January 1995 to the present. In the literature search, priority was given to original research, with highest emphasis on meta-analyses, followed by case-control and cohort studies. The Literature search excluded review articles, case reports, and articles in languages other than English. Bibliographies of articles deemed to be of the highest quality for their specific topic were combed for additional articles that may have been missed by the initial literature search. In addition, the guidelines of other professional bodies on the same, or related, topic were reviewed.

The databases were searched using the following terms: MTHFR, MTHFR polymorphism, MTHFR thermolabile variant, methylenetetrahydrofolate reductase, and hyperhomocysteinemia. Combined searches were done on specific questions of interest including: MTHFR and stroke, MTHFR and recurrent pregnancy loss, MTHFR and venous thromboembolism, and MTHFR and coronary artery disease. The same combined searches were done for hyperhomocysteinemia and stroke, etc.

Number of Source Documents

Not stated

Methods Used to Assess the Quality and Strength of the Evidence
Not stated
Rating Scheme for the Strength of the Evidence

Not applicable

Methods Used to Analyze the Evidence
Review
Description of the Methods Used to Analyze the Evidence

The articles were reviewed by the working group who provided expert consensus.

Methods Used to Formulate the Recommendations
Expert Consensus
Description of Methods Used to Formulate the Recommendations

Not stated

Rating Scheme for the Strength of the Recommendations

Not applicable

Cost Analysis

A formal cost analysis was not performed and published cost analyses were not reviewed.

Method of Guideline Validation
Internal Peer Review
Description of Method of Guideline Validation

The final manuscript was reviewed by the American College of Medical Genetics and Genomics (ACMG) Policy & Practice Guideline Committee Members, followed by the Board of Directors, and then opened up for general college membership comment.

Recommendations

Major Recommendations

American College of Medical Genetics and Genomics (ACMG) Recommendations

  • 5,10-methylenetetrahydrofolate reductase (MTHFR) polymorphism genotyping should not be ordered as part of the clinical evaluation for thrombophilia or recurrent pregnancy loss.
  • MTHFR polymorphism genotyping should not be ordered for at-risk family members.
  • A clinical geneticist who serves as a consultant for a patient in whom an MTHFR polymorphism(s) is found should ensure that the patient has received a thorough and appropriate evaluation for his or her symptoms.
  • If the patient is homozygous for the "thermolabile" variant c.665C→T, the geneticist may order a fasting total plasma homocysteine, if not previously ordered, to provide more accurate counseling.
  • MTHFR status does not change the recommendation that women of childbearing age should take the standard dose of folic acid supplementation to reduce the risk of neural tube defects as per the general population guidelines (Zacho et al., 2011; De Stefano et al., 2000; Institute of Medicine, Food and Nutrition Board, 1998; "Prevention of neural tube," 1991; Czeizel & Dudás, 1992; "Recommendations for the use of folic acid," 1992; Toriello, 2011).
Clinical Algorithm(s)

None provided

Evidence Supporting the Recommendations

References Supporting the Recommendations
Type of Evidence Supporting the Recommendations

The type of evidence supporting the recommendations is not specifically stated.

Benefits/Harms of Implementing the Guideline Recommendations

Potential Benefits

Appropriate use of 5,10-methylenetetrahydrofolate reductase (MTHFR) polymorphism testing in routine evaluation for thrombophilia

Potential Harms

Not stated

Implementation of the Guideline

Description of Implementation Strategy

An implementation strategy was not provided.

Institute of Medicine (IOM) National Healthcare Quality Report Categories

IOM Care Need
Staying Healthy
IOM Domain
Effectiveness
Patient-centeredness

Identifying Information and Availability

Bibliographic Source(s)
Hickey SE, Curry CJ, Toriello HV. ACMG practice guideline: lack of evidence for MTHFR polymorphism testing. Genet Med. 2013 Feb;15(2):153-6. [77 references] PubMed External Web Site Policy
Adaptation

Not applicable: The guideline was not adapted from another source.

Date Released
2013 Feb
Guideline Developer(s)
American College of Medical Genetics and Genomics - Professional Association
Source(s) of Funding

American College of Medical Genetics and Genomics

Guideline Committee

Not stated

Composition of Group That Authored the Guideline

Authors: Scott E. Hickey, MD, FACMG, Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA; Cynthia J. Curry, MD, FACMG, Genetic Medicine Central California, University of California, San Francisco–Fresno, Fresno, California, USA; Helga V. Toriello, PhD, FACMG, Department of Pediatrics/Human Development, Spectrum Health Hospitals and College of Medicine, Michigan State University, Grand Rapids, Michigan, USA

Financial Disclosures/Conflicts of Interest

The authors declare no conflict of interest.

Guideline Status

This is the current release of the guideline.

Guideline Availability
Availability of Companion Documents

None available

Patient Resources

None available

NGC Status

This NGC summary was completed by ECRI Institute on November 19, 2013.

Copyright Statement

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

Disclaimer

NGC Disclaimer

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

Read full disclaimer...